On February 23, 2010, 14 years ago today, the Lymphedema Treatment Act was first introduced in Congress! Click on the image to view a larger online version. If you would like a PDF version emailed to you, so that you can click on the embedded links (blue text) for additional information, please respond to this email.
 |
We also have a new easy-to-print one-pager outlining key information about the new LTA coverage that is perfect for sharing! Click HERE or on the image at the bottom of this message to view the document online and download it for printing. Note that all diagnosis codes begin with a letter, so the latter three are a capital letter “I.”
FINAL REMINDER: If you are a lymphedema therapist, today is the deadline to complete this 10-minute research survey regarding advocacy. A letter from the Doctor of Health Administration student conducting the study is below. Thank you in advance for your participation!
Heather Ferguson
Founder & Executive Director
Lymphedema Advocacy Group
LymphedemaTreatmentAct.org
Dear Certified Lymphedema Therapist:
I am a Doctor of Health Administration student under the direction of Dr. Angela Burrell in the School of Health Related Professions at the University of Mississippi Medical Center. I am conducting a research study to gain a deeper understanding of how lymphedema providers in the United States engage in and perceive advocacy and policy initiatives aimed at improving access to lymphedema treatment. My doctoral study is entitled Exploring the Landscape of Lymphedema Advocacy and Policy Advancement: A Sequential Explanatory Mixed Methods Study on Provider Engagement and Perceptions.
You have been invited to take part in this study because your perspective as a certified lymphedema therapist is valuable for understanding provider involvement in advocacy and policy. If you agree to participate, you can access the phase one survey, which takes approximately 10 minutes, through the following link: https://redcap.link/Lymphedema.
Upon completing phase one, you will have the option to further engage in phase two by providing contact information for a one-on-one interview. Your participation in this study is entirely voluntary, and there will be no consequences if you choose not to participate or decide to withdraw at any point. While the research findings may be published, your identity will remain confidential. The phase one survey is anonymous, and the results of the phase two interviews will be deidentified and safeguarded.
If you have any questions concerning the research study, please email me at tgrantham@umc.edu or Dr. Burrell at aburrell@umc.edu. By participating in the survey, you are indicating your consent to take part. Thank you for considering this opportunity.
Sincerely,
Tricia Grantham-Price, OTR/L, CLT-LANA
 |
